- ICH GCP
- EU-register voor klinische proeven
Laatste proeven
EudraCT Number: 2022-001063-27 | Sponsor Protocol Number: JZP385-202-01 | Start Date: 2023-07-19 | |||||||||||
Sponsor Name: Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc. | |||||||||||||
Full Title: A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Seve... | |||||||||||||
Medical condition: Parkinson’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002788-30 | Sponsor Protocol Number: IMVT-1401-3202 | Start Date: 2023-07-13 | |||||||||||
Sponsor Name: Immunovant Sciences, GmbH | |||||||||||||
Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED) | |||||||||||||
Medical condition: Thyroid Eye Disease (TED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) LV (Ongoing) HU (Ongoing) SK (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002006-24 | Sponsor Protocol Number: FURMO-004 | Start Date: 2023-07-13 | |||||||||||
Sponsor Name: ArriVent BioPharma, Inc. | |||||||||||||
Full Title: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients wit... | |||||||||||||
Medical condition: Treatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001396-16 | Sponsor Protocol Number: OP0595-6 | Start Date: 2023-07-07 | |||||||||||||||||||||||||||||||
Sponsor Name: Meiji Seika Pharma Co., Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Ur... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated ... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SK (Ongoing) GR (Ongoing) ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002877-27 | Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 | Start Date: 2023-07-06 | ||||||||||||||||
Sponsor Name: Cancer Trials Ireland | ||||||||||||||||||
Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P... | ||||||||||||||||||
Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004917-10 | Sponsor Protocol Number: TIGER | Start Date: 2023-06-29 | |||||||||||
Sponsor Name: King's College London [...] 1. King's College London 2. King's College Hospital NHS Foundation Trust | |||||||||||||
Full Title: Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative age-Related macular degeneration (TIGER): a phase 3, pan-European, two-gro... | |||||||||||||
Medical condition: Submacular haemorrhage secondary to exudative age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003005-30 | Sponsor Protocol Number: AR-DEX-22-03 | Start Date: 2023-06-28 | |||||||||||
Sponsor Name: Areteia Therapeutics, Inc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinop... | |||||||||||||
Medical condition: Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003584-18 | Sponsor Protocol Number: KKS-307 | Start Date: 2023-06-26 | ||||||||||||||||
Sponsor Name: Philipps University Marburg | ||||||||||||||||||
Full Title: Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia | ||||||||||||||||||
Medical condition: Progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003743-10 | Sponsor Protocol Number: BPL-003-201 | Start Date: 2023-06-22 | |||||||||||
Sponsor Name: Beckley Psytech Ltd. | |||||||||||||
Full Title: A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression | |||||||||||||
Medical condition: Treatment-Resistant Depression (TRD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) PL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000430-42 | Sponsor Protocol Number: 67953964MDD3003_VENTURA-LT | Start Date: 2023-06-22 | |||||||||||
Sponsor Name: Janssen-Cilag International NV | |||||||||||||
Full Title: An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) HU (Ongoing) CZ (Ongoing) PL (Ongoing) BG (Ongoing) ES (Ongoing) PT (Ongoing) SK (Ongoing) | |||||||||||||
Trial results: (No results available) |